Intrapulmonary pharmacokinetics of high doses of tigecycline in patients with ventilator-associated pneumonia-Reference-Cited by-同舟云学术

Intrapulmonary pharmacokinetics of high doses of tigecycline in patients with ventilator-associated pneumonia

Published:2022-01 Issue:1 Volume:59 Page:106487
ISSN:0924-8579
Container-title:International Journal of Antimicrobial Agents
language:en
Short-container-title:International Journal of Antimicrobial Agents

Author:

Dimopoulos G.,Almyroudi M.P.^ORCID,Kapralos I.,Apostolopoulou O.^ORCID,Flevari A.,Nicolau D.P.^ORCID,Dokoumetzidis A.

Publisher

Elsevier BV

Subject

Pharmacology (medical),Infectious Diseases,Microbiology (medical),General Medicine

Reference31 articles.

1. Steady-state serum and intrapulmonary pharmacokinetics and pharmacodynamics of tigecycline;Conte;Int J Antimicrob Agents,2005

2. FDA drug safety communication: FDA warns of increased risk of death with IV antibacterial Tygacil (tigecycline) and approves new Boxed Warning,2013

3. All-cause mortality imbalance in the tigecycline phase 3 and 4 clinical trials;McGovern;Int J Antimicrob Agents,2013

4. Comparison of tigecycline with imipenem/cilastatin for the treatment of hospital-acquired pneumonia;Freire;Diagn Microbiol Infect Dis,2010

5. Excess deaths associated with tigecycline after approval based on noninferiority trials;Prasad;Clin Infect Dis,2012

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Risk factors for mortality in Acinetobacter baumannii bloodstream infections and development of a predictive mortality model;Journal of Global Antimicrobial Resistance;2024-09

2. Current and novel therapies for management of Acinetobacter baumannii -associated pneumonia;Critical Reviews in Microbiology;2024-07

3. Repurposing harmaline as a novel approach to reverse tmexCD1-toprJ1-mediated tigecycline resistance against klebsiella pneumoniae infections;Microbial Cell Factories;2024-05-24

4. In vitro antimicrobial susceptibility data of global meropenem-resistant Acinetobacter baumannii isolates causing pneumonia: Data from the Antimicrobial Testing Leadership and Surveillance Program, 2014–2021, and re-estimations of susceptibility breakpoints and appropriate dosages of important antibiotics for pneumonia treatment;Journal of Global Antimicrobial Resistance;2024-03

5. Clinical outcomes and safety of intravenous polymyxin B-based treatment in critically ill patients with carbapenem-resistant Acinetobacter baumannii nosocomial pneumonia;International Journal of Antimicrobial Agents;2023-08